Abstract View

Author(s): Soham Mandal*1, Moumita karmakar2

Email(s): 1soham.mandal@tnu.in

Address:

    Department of pharmaceutics, School of Pharmacy, The Neotia University, West Bengal.

Published In:   Volume - 2,      Issue - 3,     Year - 2023

DOI: Not Available

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
In industrialised nations, cardiovascular disease (CVD) is the vital cause of death and morbidity. Atherosclerotic lesions that narrow the arterial lumen are the cause of CVD. Development of plaque, reduces blood flow to the heart and usually causes serious consequences. Medication delivery methods alter the drug release profile, absorption, and distribution to treat various disorders while enhancing the effectiveness and safety of the final product. In the rapidly developing field of nanomedicine, materials on the nanoscale are employed as therapeutic agents. The nano-drug delivery system has distinguished itself as an excellent platform for delivering therapeutic agents to a sick location in a more regulated and targeted manner among all the other fascinating uses of nanomaterials. Through site-specificity, reduced toxicity, and target-oriented administration, nanotechnology aims to treat terrifying illnesses while providing various advantages. This review discusses new computer simulations of magnetically targeted nano-pharmacodynamics, nanoparticles, and nano-drug delivery devices.

Cite this article:
Soham Mandal*, Moumita karmakar. Computational Nano- Pharmacodynamics in Cardiovascular Diseases. IJRPAS, March-April 2023; 2(2): 35-43


References not available.

Related Images:



Recent Images



Neurological Complications among Pregnant and Post Partum Mothers in a Private Hospital, Yogyakarta, Indonesia
Review on Regulatory Affairs in Pharmaceutical Industry
Cucumber and Mint Soap: Preparation and Evaluation
Topical Delivery in Cosmetics: Enhancing Penetration and Bioavailability
Formulation and Evaluation of Polyherbal Soap
Gelatin: A Widely Used Pharmaceutical Excipient
Therapeutic insights into Saroglitazar: a dual PPAR- α/γ agonist targeting diabetic dyslipidaemia and NAFLD
A Comprehensive Review on Dyslipidemia and Obesity: Pathophysiology, Clinical Implications and Management Approaches
Antidiabetic Herbs and Polyherbal Antidiabetic Formulations –An Overview
Review on Clinical Research and Clinical Trials

Tags